Sumitomo Pharma America, Inc.

Sumitomo Pharma America, Inc. (SMPA) is a biopharmaceutical company focused on psychiatry, neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies.[1] SMPA has six commercial products and more than 30 early- to late-stage drug assets. SMPA’s headquarters is in Cambridge, Massachusetts. Other U.S. locations include California, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania and Washington D.C. SMPA maintains global operations with affiliate site locations in Canada, the UK and Basel and Zug, Switzerland. SMPA is a Sumitomo Pharma Company.[2]

Sumitomo Pharma America, Inc.
IndustryBiotech & Pharmaceuticals
Founded2023
Headquarters
Cambridge, Massachusetts
Key people
Myrtle Potter, (President and CEO)
Products
ParentSumitomo Pharma
Websiteus.sumitomo-pharma.com

History

SMPA was formed following the combination of several wholly-owned U.S. subsidiaries of its parent company, Sumitomo Pharma. SMPA combined the following companies:

  • Sumitovant Biopharma Ltd.
  • Myovant Sciences, Inc.
  • Urovant Sciences, Inc.
  • Enzyvant Therapeutics, Inc.
  • Sumitomo Pharma America Holdings, Inc.
  • Sumitomo Pharma Oncology, Inc.
  • Sunovion Pharmaceuticals Inc.

Spirovant Sciences, Inc. is a wholly owned subsidiary of Sumitomo Pharma America.[3]

References
  1. "US Sumitomo Pharma Subsidiaries Combine to Form Sumitomo Pharma America". American Pharmaceutical Review. 7 April 2023. Retrieved 10 July 2023.
  2. "Sumitomo Pharma tidies 7 units into one combined US entity in spring cleaning". FierceBiotech. 3 April 2023. Retrieved 10 July 2023.
  3. jirehl (2023-04-17). "Sumitomo Subsidiaries Submit to Super Synthesization to Form Sumitomo Pharma America | The Healthcare Technology Report". Retrieved 2023-07-28.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.